Lucid Diligence Brief: Shuttle Pharma x Molecule.ai LOI
Lucid Diligence Brief: Shuttle Pharma x Molecule.ai LOI Professional audiences…
Lucid Diligence Brief: Ascenta Capital Fund I, $325M final close
Lucid Diligence Brief: Ascenta Capital Fund I, $325M final close Professional…
Trending in Health Mobile Apps H1 2025
📊 Trending in Health Mobile Apps: Current Trends, Rankings and Insights from H1…
ENDO 2025 Preview: Endocrinology Highlights to Watch
ENDO 2025 at a glance Get ready for ENDO 2025, where Endocrinology…
Cell and Gene Therapy Weekly News - June 5th 2025
This Week in Gene & Cell Therapy: Breakthrough Trials, Fast Track…
Cell and Gene Therapy Weekly News - May 29th 2025
This Week in Gene & Cell Therapy: Clinical Trial Expansions, Rare Disease…
Cell and Gene Therapy Weekly News - May 8th 2025
This Week in Gene & Cell Therapy: Gene Therapy Milestones, Strategic…
Cell and Gene Therapy Clinical Trials 2025 Edition
Introduction Cell and gene therapy (CGT) represents a groundbreaking frontier…
mRNA personalized Cancer Vaccines: BioNTech and Moderna Race to the Finish Line
With the emergence of immunotherapy for oncology, cancer vaccines are cropping…
How a leading pharma company stayed updated with the latest solid tumors early stage advancements presented at AACR
The Challenge: Capturing the latest developments in the solid tumors space…
How we helped a Japanese innovator in cancer Dx estimate its market size and understand the future market dynamics
The challenge: Estimating the market size of innovative cancer Dx in Japan A…